Saturday, January 17, 2026 | 09:42 PM ISTहिंदी में पढें
Anthem Biosciences Ltd News
Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms
While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs
 "Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms")
Updated On : 09 Jan 2026 | 11:20 AM IST
Nomura initiates Anthem with 'Buy', sees strong long-term CRDMO runway
The brokerage cited the company's strong positioning in India's fast-growing CRDMO space, high profitability and disciplined execution as reasons for its bullish view
 "Nomura initiates Anthem with 'Buy', sees strong long-term CRDMO runway")
Updated On : 28 Nov 2025 | 8:33 AM IST
Recently listed biotech stock surges 44% against issue price; time to sell?
Shares of Anthem Biosciences surged 9 per cent to ₹820 on the BSE in Thursday's intra-day trade amid heavy volumes after reporting a strong earnings for the quarter ended June 2025.
 "Recently listed biotech stock surges 44% against issue price; time to sell?")
Updated On : 14 Aug 2025 | 11:00 AM IST
Anthem Biosciences lists at 27% premium; should you book profit or hold?
Anthem Biosciences shares listed at ₹723.10 per share on the BSE and ₹723.05 per share on the NSE, compared to the issue price of ₹570 per share
 "Anthem Biosciences lists at 27% premium; should you book profit or hold?")
Updated On : 21 Jul 2025 | 10:00 AM IST